Skip to main content

Articles

Page 28 of 62

  1. Diabetes has been reported to be associated with carotid artery plaque (CAP). However, it remains unclear whether hemoglobin A1c (HbA1c) level, a marker for long-term glycemic status, is associated with altere...

    Authors: Renying Xu, Ting Zhang, Yanping Wan, Zhuping Fan and Xiang Gao
    Citation: Cardiovascular Diabetology 2019 18:153
  2. Daily glucose variability may contribute to vascular complication development irrespective of mean glucose values. The incremental glucose peak (IGP) during an oral glucose tolerance test (OGTT) can be used as...

    Authors: Yuri D. Foreman, Martijn C. G. J. Brouwers, Tos T. J. M. Berendschot, Martien C. J. M. van Dongen, Simone J. P. M. Eussen, Marleen M. J. van Greevenbroek, Ronald M. A. Henry, Alfons J. H. M. Houben, Carla J. H. van der Kallen, Abraham A. Kroon, Koen D. Reesink, Miranda T. Schram, Nicolaas C. Schaper and Coen D. A. Stehouwer
    Citation: Cardiovascular Diabetology 2019 18:152
  3. The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special intere...

    Authors: Cristina Razquin, Miguel Ruiz-Canela, Clary B. Clish, Jun Li, Estefania Toledo, Courtney Dennis, Liming Liang, Albert Salas-Huetos, Kerry A. Pierce, Marta Guasch-Ferré, Dolores Corella, Emilio Ros, Ramon Estruch, Enrique Gómez-Gracia, Montse Fitó, Jose Lapetra…
    Citation: Cardiovascular Diabetology 2019 18:151
  4. Insulin resistance (IR) is considered a pivotal risk factor for cardiometabolic diseases, and the triglyceride–glucose index (TyG index) has emerged as a reliable surrogate marker of IR. Although several recen...

    Authors: Erfei Luo, Dong Wang, Gaoliang Yan, Yong Qiao, Bo Liu, Jiantong Hou and Chengchun Tang
    Citation: Cardiovascular Diabetology 2019 18:150
  5. Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL...

    Authors: Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic and Lawrence A. Leiter
    Citation: Cardiovascular Diabetology 2019 18:149
  6. Excessive reactive oxygen species from endothelial mitochondria in type 2 diabetes individuals (T2DM) may occur through multiple related mechanisms, including production of mitochondrial reactive oxygen specie...

    Authors: Mamatha Kakarla, Venkata K. Puppala, Sudhi Tyagi, Amberly Anger, Kathryn Repp, Jingli Wang, Rong Ying and Michael E. Widlansky
    Citation: Cardiovascular Diabetology 2019 18:148
  7. Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help ...

    Authors: Annunziata Nusca, Dario Tuccinardi, Claudio Proscia, Rosetta Melfi, Silvia Manfrini, Antonio Nicolucci, Antonio Ceriello, Paolo Pozzilli, Gian Paolo Ussia, Francesco Grigioni and Germano Di Sciascio
    Citation: Cardiovascular Diabetology 2019 18:147
  8. Reverse cholesterol transport (RCT) is an important cardioprotective mechanism and the decrease in cholesterol efflux can result in the dyslipidemia. Although liraglutide, a glucagon like peptide-1 analogue, h...

    Authors: Ya-Ru Wu, Xiao-Yun Shi, Chun-Yan Ma, Yue Zhang, Rui-Xia Xu and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2019 18:146
  9. Mortality attributable to heart failure remains high. The prevalence of heart failure in patients with diabetes mellitus ranges from 19 to 26%. It is estimated that up to 21.1 million adults in the United Stat...

    Authors: Marcello Ricardo Paulista Markus, Susanne Rospleszcz, Till Ittermann, Sebastian Edgar Baumeister, Sabine Schipf, Ulrike Siewert-Markus, Roberto Lorbeer, Corinna Storz, Violetta Ptushkina, Annette Peters, Christa Meisinger, Fabian Bamberg, Matthias Nauck, Martin Bahls, Henry Völzke, Stephan Burkhard Felix…
    Citation: Cardiovascular Diabetology 2019 18:145
  10. Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study.

    Authors: Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina and Danilo Neglia
    Citation: Cardiovascular Diabetology 2019 18:144
  11. Excess fat deposition could induce phenotypic changes of perivascular adipose tissue (PVAT remodeling), which may promote the progression of atherosclerosis via modulation of adipocytokine secretion. However, ...

    Authors: Yusaku Mori, Michishige Terasaki, Munenori Hiromura, Tomomi Saito, Hideki Kushima, Masakazu Koshibu, Naoya Osaka, Makoto Ohara, Tomoyasu Fukui, Hirokazu Ohtaki, Hirano Tsutomu and Sho-ichi Yamagishi
    Citation: Cardiovascular Diabetology 2019 18:143
  12. Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the associatio...

    Authors: Patric Winzap, Allan Davies, Roland Klingenberg, Slayman Obeid, Marco Roffi, François Mach, Lorenz Räber, Stephan Windecker, Christian Templin, Fabian Nietlispach, David Nanchen, Baris Gencer, Olivier Muller, Christian M. Matter, Arnold von Eckardstein and Thomas F. Lüscher
    Citation: Cardiovascular Diabetology 2019 18:142
  13. Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investiga...

    Authors: Natia Peradze, Olivia M. Farr, Nikolaos Perakakis, Iolanda Lázaro, Aleix Sala-Vila and Christos S. Mantzoros
    Citation: Cardiovascular Diabetology 2019 18:141
  14. Gestational diabetes mellitus (GDM) is defined as the presence of high blood glucose levels with the onset, or detected for the first time during pregnancy, as a result of increased insulin resistance. GDM may...

    Authors: A. Lorenzo-Almorós, T. Hang, C. Peiró, L. Soriano-Guillén, J. Egido, J. Tuñón and Ó. Lorenzo
    Citation: Cardiovascular Diabetology 2019 18:140
  15. The aim of the present study was to identify a threshold for the cholesterol level at which the risk of cardiovascular disease (CVD) begins to increase in people with type 2 diabetes mellitus (DM).

    Authors: Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song and Hyuk-Sang Kwon
    Citation: Cardiovascular Diabetology 2019 18:139
  16. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanism...

    Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:138
  17. Visceral fat area (VFA) is a good surrogate marker of obesity-related disorders, such as hypertension, dyslipidemia and glucose intolerance. Although estimating the VFA by X-ray computed tomography (CT) is the...

    Authors: Yoko Omura-Ohata, Cheol Son, Hisashi Makino, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Ichiro Kishimoto and Kiminori Hosoda
    Citation: Cardiovascular Diabetology 2019 18:137
  18. Diabetes mellitus (DM) or pre-diabetes status is closely associated with features of vulnerable coronary lesions in patients with stable coronary heart disease or acute coronary syndrome. However, the associat...

    Authors: Zhaoxue Sheng, Peng Zhou, Chen Liu, Jiannan Li, Runzhen Chen, Jinying Zhou, Li Song, Hanjun Zhao and Hongbing Yan
    Citation: Cardiovascular Diabetology 2019 18:136
  19. Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs wi...

    Authors: Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:135
  20. The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism s...

    Authors: Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Jing Sun, Qian Dong and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2019 18:134
  21. The pathogenesis and cardiovascular impact of type 2 diabetes (T2D) may be different in South Asians compared with other ethnic groups. The phenotypic characterization of diabetic cardiomyopathy remains debate...

    Authors: Elisabeth H. M. Paiman, Huub J. van Eyk, Maurice B. Bizino, Ilona A. Dekkers, Paul de Heer, Johannes W. A. Smit, Ingrid M. Jazet and Hildo J. Lamb
    Citation: Cardiovascular Diabetology 2019 18:133
  22. Diabetes mellitus (DM) is a major cause of morbidity and mortality following heart transplantation (HT), with 21% and 35% of survivors being affected within 1 and 5 years following HT, respectively. Magnesium ...

    Authors: Yael Peled, Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Enrique Z. Fisman, Dov Freimark, Robert Klempfner, Leonid Sternik and Michael Shechter
    Citation: Cardiovascular Diabetology 2019 18:132
  23. Accumulating evidence has shown that type 2 diabetes (T2D) and coronary artery disease (CAD) may stem from a ‘common soil’. The aim of our study was to examine the association between genetic predisposition to...

    Authors: Qiwen Zheng, Jie Jiang, Yong Huo and Dafang Chen
    Citation: Cardiovascular Diabetology 2019 18:131
  24. Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with d...

    Authors: Julie R. Lundgren, Kristine Færch, Daniel R. Witte, Anna E. Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Jens J. Holst, Dorte Vistisen, Marit E. Jørgensen, Signe S. Torekov and Nanna B. Johansen
    Citation: Cardiovascular Diabetology 2019 18:130
  25. Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2019 18:129
  26. Being obese or underweight, and having diabetes are important risk factors for new-onset atrial fibrillation (AF). However, it is unclear whether there is any interaction between body weight and diabetes in re...

    Authors: Yun Gi Kim, Kyung-Do Han, Jong-Il Choi, Ki Yung Boo, Do Young Kim, Suk-Kyu Oh, Kwang-No Lee, Jaemin Shim, Jin Seok Kim and Young-Hoon Kim
    Citation: Cardiovascular Diabetology 2019 18:128
  27. Dyslipidaemia and low-grade inflammation are central in atherogenesis and linked to overweight and physical inactivity. Lifestyle changes are important in secondary prevention of coronary artery disease (CAD)....

    Authors: Lene Rørholm Pedersen, Rasmus Huan Olsen, Christian Anholm, Arne Astrup, Jesper Eugen-Olsen, Mogens Fenger, Lene Simonsen, Rosemary L. Walzem, Steen Bendix Haugaard and Eva Prescott
    Citation: Cardiovascular Diabetology 2019 18:127
  28. Pericoronary adipose tissue inflammation might lead to the development and destabilization of coronary plaques in prediabetic patients. Here, we evaluated inflammation and leptin to adiponectin ratio in perico...

    Authors: Celestino Sardu, Nunzia D’Onofrio, Michele Torella, Michele Portoghese, Francesco Loreni, Simone Mureddu, Giuseppe Signoriello, Lucia Scisciola, Michelangela Barbieri, Maria Rosaria Rizzo, Marilena Galdiero, Marisa De Feo, Maria Luisa Balestrieri, Giuseppe Paolisso and Raffaele Marfella
    Citation: Cardiovascular Diabetology 2019 18:126
  29. Insulin resistance (IR) is considered as a risk factor for atrial fibrillation (AF) even before diabetes develops. The pathophysiology and underlying mechanism are largely unclear.

    Authors: Yi-Hsin Chan, Gwo-Jyh Chang, Ying-Ju Lai, Wei-Jan Chen, Shang-Hung Chang, Li-Man Hung, Chi-Tai Kuo and Yung-Hsin Yeh
    Citation: Cardiovascular Diabetology 2019 18:125
  30. Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing ca...

    Authors: Boris Fishman, Gadi Shlomai, Gilad Twig, Estela Derazne, Alexander Tenenbaum, Enrique Z. Fisman, Adi Leiba and Ehud Grossman
    Citation: Cardiovascular Diabetology 2019 18:124
  31. Patients with Diabetes mellitus (DM) are susceptible to coronary artery disease (CAD). However, the impact of DM on plaque progression in the non-stented segments of stent-implanted patients has been rarely re...

    Authors: Rui Shi, Ke Shi, Zhi-gang Yang, Ying-kun Guo, Kai-yue Diao, Yue Gao, Yi Zhang and Shan Huang
    Citation: Cardiovascular Diabetology 2019 18:123
  32. Coronary calcification is associated with high risk for cardiovascular events. However, its impact on plaque vulnerability is incompletely understood. In the present study we defined the intrinsic calcificatio...

    Authors: Sebastian Reith, Andrea Milzi, Enrico Domenico Lemma, Rosalia Dettori, Kathrin Burgmaier, Nikolaus Marx and Mathias Burgmaier
    Citation: Cardiovascular Diabetology 2019 18:122
  33. Both obesity and type 2 diabetes are important risk factors for atrial fibrillation (AF), possibly because they both cause an expansion of epicardial adipose tissue, which is the source of proinflammatory adip...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2019 18:121
  34. To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin.

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang and Edward Chia-Cheng Lai
    Citation: Cardiovascular Diabetology 2019 18:120
  35. Recently, several randomized trials have noted improved outcomes with staged percutaneous coronary intervention (PCI) of nonculprit vessels in patients with ST-segment elevation myocardial infarction (STEMI) a...

    Authors: Kongyong Cui, Shuzheng Lyu, Hong Liu, Xiantao Song, Fei Yuan, Feng Xu, Min Zhang, Wei Wang, Mingduo Zhang, Dongfeng Zhang and Jinfan Tian
    Citation: Cardiovascular Diabetology 2019 18:119
  36. Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treat...

    Authors: Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Robert Klempfner, Enrique Z. Fisman, Elad Maor, Tal Ovdat, Sergei Amunts, Leonid Sternik and Yael Peled
    Citation: Cardiovascular Diabetology 2019 18:118
  37. Complication screening is recommended for patients with type 2 diabetes (T2D), but the optimal screening intensity and schedules are unknown. In this study, we evaluated whether intensive versus standard compl...

    Authors: Mario Luca Morieri, Enrico Longato, Marta Mazzucato, Barbara Di Camillo, Arianna Cocchiglia, Lorenzo Gubian, Giovanni Sparacino, Angelo Avogaro, Gian Paolo Fadini and Saula Vigili de Kreutzenberg
    Citation: Cardiovascular Diabetology 2019 18:117
  38. To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

    Authors: Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:116
  39. EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular di...

    Authors: Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč…
    Citation: Cardiovascular Diabetology 2019 18:115
  40. Cardiac fat is a cardiovascular biomarker but its importance in patients with type 2 diabetes is not clear. The aim was to evaluate the predictive potential of epicardial (EAT), pericardial (PAT) and total car...

    Authors: Regitse H. Christensen, Bernt Johan von Scholten, Christian S. Hansen, Magnus T. Jensen, Tina Vilsbøll, Peter Rossing and Peter G. Jørgensen
    Citation: Cardiovascular Diabetology 2019 18:114
  41. In the light of growing global epidemic of type 2 diabetes mellitus (T2DM), significant efforts are made to discover next-generation biomarkers for early detection of the disease. Multiple mechanisms including...

    Authors: Justyna Pordzik, Daniel Jakubik, Joanna Jarosz-Popek, Zofia Wicik, Ceren Eyileten, Salvatore De Rosa, Ciro Indolfi, Jolanta M. Siller-Matula, Pamela Czajka and Marek Postula
    Citation: Cardiovascular Diabetology 2019 18:113
  42. Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new ...

    Authors: Yue Fei, Man-Fung Tsoi and Bernard Man Yung Cheung
    Citation: Cardiovascular Diabetology 2019 18:112
  43. There is no clearly defined temporal relationship between arterial stiffness and diabetes. We aimed to investigate the prospective association between baseline brachial–ankle pulse wave velocity (baPWV) and th...

    Authors: Yuanyuan Zhang, Panpan He, Youbao Li, Yan Zhang, Jianping Li, Min Liang, Guobao Wang, Genfu Tang, Yun Song, Binyan Wang, Chengzhang Liu, Lishun Liu, Yimin Cui, Xiaobin Wang, Yong Huo, Xiping Xu…
    Citation: Cardiovascular Diabetology 2019 18:111
  44. The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albumi...

    Authors: Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Kazutaka Aoki, Gen Yasuda, Taishi Yoshii, Takayuki Yamada, Syuji Ono, Tomoko Shibasaki-Kurita…
    Citation: Cardiovascular Diabetology 2019 18:110
  45. Inflammation and insulin resistance play crucial roles in the development of type 2 diabetes mellitus (T2DM). We aim to examine the temporal relationship between high-sensitivity C-reactive protein (hsCRP) and...

    Authors: Yinkun Yan, Shengxu Li, Yang Liu, Lydia Bazzano, Jiang He, Jie Mi and Wei Chen
    Citation: Cardiovascular Diabetology 2019 18:109
  46. The territory of the right coronary artery (RCA) is smaller than that of the left anterior descending artery. Previous studies have reported conflicting results when considering whether stable RCA-chronic tota...

    Authors: Yunfeng Yan, Mingduo Zhang, Fei Yuan, Hong Liu, Di Wu, Yudong Fan, Xinjing Guo, Feng Xu, Min Zhang, Quanming Zhao and Shuzheng Lyu
    Citation: Cardiovascular Diabetology 2019 18:108
  47. Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, ...

    Authors: Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu and Yafeng Zhou
    Citation: Cardiovascular Diabetology 2019 18:107
  48. Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. The purpose of this study was to asses...

    Authors: Zengliang Wang, Bo Li, Yongxin Wang, Aisha Maimaitili, Hu Qin, Geng Dangmurenjiafu and Shuo Wang
    Citation: Cardiovascular Diabetology 2019 18:105
  49. To examine the effect of high-intensity interval training (HIIT) on metabolic syndrome (MetS) and body composition in cardiac rehabilitation (CR) patients with myocardial infarction (MI).

    Authors: Yaoshan Dun, Randal J. Thomas, Joshua R. Smith, Jose R. Medina-Inojosa, Ray W. Squires, Amanda R. Bonikowske, Hsuhang Huang, Suixin Liu and Thomas P. Olson
    Citation: Cardiovascular Diabetology 2019 18:104
  50. We investigated the association regarding severe hypoglycemia episodes with cardiovascular disease risk and all-cause mortality in patients with type 2 diabetes.

    Authors: Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Seon-Ah Cha, Yu-Bae Ahn and Seung-Hyun Ko
    Citation: Cardiovascular Diabetology 2019 18:103

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115